Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

Abouelyazeed Apr. 17 at 10:15 AM

$BFRG $PFE $LLY $ABT

0 · Reply

DragonAlgo Apr. 17 at 3:02 AM

🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-17 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.29 Stop: $0.21 TP1: $0.38 TP2: $0.49 TP3: $0.70 🔗 https://dragonalgo.com

0 · Reply

doubleuptwice Apr. 17 at 1:25 AM

$PFE from what I’m seeing tomorrow could be a really big day for pfharma. And if my buy today based on my analysis of where pfe sits right now I would not be surprised to finally see a 5%+ day tomorrow

1 · Reply

dewmoore Apr. 17 at 12:29 AM

$SLS The Super Bowl of Cancer Research is HERE! Friday at #AACR26, the world will watch as the next generation of medicine moves from "killing" cancer to reprogramming it. As featured in The Atlantic, we are seeing treatments do things scientists NEVER thought possible. Back in the Day, immunotherapy was a gamble. Weak peptides, toxic side effects, and "dirty" treatments that hit everything + cancer cells that knew how to stay "invisible." Today? We're talkin therapies like SLS-009 that: Crash cancer’s shields (MCL-1/Survivin) in 6 HOURS. Get STRONGER with each dose (Reversing resistance). Are so precise they’re being eyed to cure Autoimmune diseases like Lupus and MS. The "Atomic Bombs" of data drop Tuesday. The pioneers dreamed of this sh*t... we’re living it. 🚀 Read the shift: 1) MSK History: The History and Future of Cancer Vaccines https://www.mskcc.org/news/history-and-future-of-cancer-vaccines-at-msk 2)The Atlantic: CAR-T for Autoimmune Disease https://www.theatlantic.com/science/2026/04/car-t-cell-therapy-autoimmune-disease/686742/ Hey $LLY $MRK $PFE we await ALL starter bids at $70+

0 · Reply

Gorginabailey Apr. 16 at 10:31 PM

$SLS $SLS #Blockbuster_potential (e.g., expansion to ovarian, lung, or breast cancer maintenance, plus buyout interest from big pharma like $MRK / $PFE RECENT share count, might translate to $120+ per share 🤑🤑🤑🤑 #not financial advice

1 · Reply

parcha Apr. 16 at 9:49 PM

https://youtube.com/watch?v=ebS2-bBmoyI&si=PanK7zdwD7J2RZ3w $PFE $V $SYF

0 · Reply

PFElinepfrenzy1990 Apr. 16 at 8:58 PM

$PFE - COME ON ALBERT STOP DOING THE PHANTOM 👻 STOCK UNITS THINGY AND BUY ACTUAL SHARES ALBERT PLEASE

0 · Reply

Tiger65 Apr. 16 at 8:41 PM

$PFE that’s a good question. It definitely closed green on Friday after the last ER. I understand the actual slightly bearish sentiment due to the selloff that was caused by profittaking in my opinion. The stock has clearly lost shortterm momentum. Uptrend is still intact thoug. The one good thing about the company is that it is definitely not a one-trick pony. I’m inclined to believe that the management has invested that massive cash from Covid drugs wisely somehow and it will pay off in the future. But who can tell the future.

0 · Reply

doubleuptwice Apr. 16 at 8:20 PM

$PFE when was the last time this ran on a Friday?

1 · Reply

Tiger65 Apr. 16 at 7:48 PM

$PFE The stock just got a longterm recommendation from Schwab analysts due to the recent selloff. It looks cheap again, and they think it will continue to climb on the longer term. https://www.youtube.com/watch?v=ebS2-bBmoyI We might be headed into a surprise move in a week when we get a forcast for the ER and R&D. It will be interesting to hear about Metsera drugs stage development. The drugs seem to be longer lasting then it’s competitors.

0 · Reply

The Big 3: PFE, V, SYF

SYF V

Apr 10, 2026, 11:00 PM EDT - 6 days ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 9, 2026, 10:00 AM EDT - 7 days ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 7, 2026, 1:54 PM EDT - 9 days ago

Why Is Pfizer Stock Dropping Tuesday?

Apr 2, 2026, 11:14 AM EDT - 14 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Apr 1, 2026, 11:39 AM EDT - 15 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Apr 1, 2026, 10:13 AM EDT - 15 days ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Mar 30, 2026, 10:44 AM EDT - 17 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Mar 24, 2026, 10:00 AM EDT - 23 days ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 23, 2026, 12:46 PM EDT - 24 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Mar 23, 2026, 10:35 AM EDT - 24 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Mar 23, 2026, 9:36 AM EDT - 24 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Mar 23, 2026, 7:07 AM EDT - 24 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Mar 23, 2026, 7:02 AM EDT - 24 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Mar 23, 2026, 6:47 AM EDT - 24 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Mar 23, 2026, 6:45 AM EDT - 24 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

Mar 22, 2026, 9:45 AM EDT - 25 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Mar 20, 2026, 4:30 PM EDT - 27 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 19, 2026, 6:45 AM EDT - 4 weeks ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 18, 2026, 2:23 PM EDT - 4 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 17, 2026, 7:49 AM EDT - 4 weeks ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 6:45 AM EDT - 4 weeks ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 9, 2026, 7:27 AM EDT - 5 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 6, 2026, 12:40 AM EST - 6 weeks ago

China approves Pfizer GLP-1 drug for weight management

Mar 5, 2026, 4:48 PM EST - 6 weeks ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 4, 2026, 8:55 AM EST - 6 weeks ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Mar 3, 2026, 8:10 AM EST - 6 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Mar 2, 2026, 11:14 AM EST - 6 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership

Feb 27, 2026, 10:00 AM EST - 6 weeks ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 24, 2026, 2:29 PM EST - 7 weeks ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 7:45 AM EST - 7 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 23, 2026, 10:26 PM EST - 7 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 3:15 PM EST - 7 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Feb 23, 2026, 10:00 AM EST - 7 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 18, 2026, 12:00 PM EST - 2 months ago

Is There 25% Downside For Pfizer Stock?

Feb 17, 2026, 6:45 AM EST - 2 months ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 13, 2026, 6:13 AM EST - 2 months ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

Feb 12, 2026, 8:05 AM EST - 2 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Feb 11, 2026, 8:56 AM EST - 2 months ago

Is Pfizer Stock Now A Value Trap?

Feb 10, 2026, 3:20 PM EST - 2 months ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 6, 2026, 2:55 PM EST - 2 months ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 6:45 AM EST - 2 months ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 5, 2026, 7:09 PM EST - 2 months ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Feb 3, 2026, 12:00 PM EST - 2 months ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 11:17 AM EST - 2 months ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Feb 3, 2026, 10:15 AM EST - 2 months ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 8:50 AM EST - 2 months ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:17 AM EST - 2 months ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Abouelyazeed Apr. 17 at 10:15 AM

$BFRG $PFE $LLY $ABT

0 · Reply

DragonAlgo Apr. 17 at 3:02 AM

0 · Reply

doubleuptwice Apr. 17 at 1:25 AM

1 · Reply

dewmoore Apr. 17 at 12:29 AM

0 · Reply

Gorginabailey Apr. 16 at 10:31 PM

1 · Reply

parcha Apr. 16 at 9:49 PM

https://youtube.com/watch?v=ebS2-bBmoyI&si=PanK7zdwD7J2RZ3w $PFE $V $SYF

0 · Reply

PFElinepfrenzy1990 Apr. 16 at 8:58 PM

$PFE - COME ON ALBERT STOP DOING THE PHANTOM 👻 STOCK UNITS THINGY AND BUY ACTUAL SHARES ALBERT PLEASE

0 · Reply

Tiger65 Apr. 16 at 8:41 PM

0 · Reply

doubleuptwice Apr. 16 at 8:20 PM

$PFE when was the last time this ran on a Friday?

1 · Reply

Tiger65 Apr. 16 at 7:48 PM

0 · Reply

zerodayrounder Apr. 16 at 7:48 PM

is there a big battle brewing between $PFE IV drug emblaveo and $GSK oral tebipenem at ESCMID? wonder how $SPRO situated in between here?

1 · Reply

Micheal_Pothead Apr. 16 at 7:39 PM

$PFE holy pinned

1 · Reply

Typecheck Apr. 16 at 6:45 PM

$PFE volume dried up. What is happening?

1 · Reply

Micheal_Pothead Apr. 16 at 5:43 PM

$PFE red lol

0 · Reply

Micheal_Pothead Apr. 16 at 5:35 PM

$PFE basically flat for 2 months now

1 · Reply

PFElinepfrenzy1990 Apr. 16 at 5:13 PM

$PFE - In a very parallel world, we're pulling an Intel

1 · Reply

Abouelyazeed Apr. 16 at 4:58 PM

$BFRG Trump signals U.S. support for psychedelic PTSD treatments—igniting a new wave of biotech and AI-driven drug discovery plays like BFRG. $LLY $PFE $JNJ $NVS

0 · Reply

IndyOne Apr. 16 at 4:45 PM

$MRNA Moderna is an absolute work horse. V940 clinical results for Melanoma and NSCLC (Non-Small Cell Lung Cancer). V940 platform expansion includes renal cell carcinoma and bladder cancer. CEO committed to 10%+ revenue growth 2026. TELLS: October 2025: "Deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel, Moderna CEO, sold his six-level home in Boston where he had lived for +12 years. January 2026: Moderna and Merck announced V940 results showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved. NO ROYALTIES! HUGE WIN. Moderna wanted the decks clear, they could have fought this longer like Pfizer & BioNtech. Partnership or buyout coming from $MRK $PFE $RHHBY or $GSK .

0 · Reply

RichMitch Apr. 16 at 4:42 PM

$VVOS $LLY $BMY $PFE $REPL

0 · Reply

stockanalysis_ Apr. 16 at 4:38 PM

Here's How To Use StockAnalysis.com As a Full-Time Dividend Investor! $PFE $PEP $MO $VZ $KO https://www.youtube.com/watch?v=zY6rAhu_wng

0 · Reply

RichMitch Apr. 16 at 4:33 PM

$VVOS 👀 Hmmm 🤔 $LLY $BMY $PFE $SPY

0 · Reply

BioRich Apr. 16 at 4:32 PM

$CMND the next runner? Recently hit Alcohol Use Disorder (AUD) trial Primary Endpoint. Did a raise, so that's behind us, and I believe federal regulations are around the corner supporting this type of treatment. Cheap so worth the risk IMHO. Follow/Subscribe for more suggestions and perspective. Would love to hear yours. that's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $ALT $LLY $PFE

0 · Reply

Market Cap	154.61B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.39
Forward PE	9.09
Profit Margin	12.42%
Debt to Equity Ratio	0.75

Volume	21,905,200
Avg Vol	40,600,605
Day's Range	N/A - N/A
Shares Out	5.69B
Stochastic %K	35%
Beta	0.43
Analysts	Sell
Price Target	$29.05